Deprescribing (January)

Date of Issue: 01/01/2019 | Volume: 17 | Number: 1

Issue Links:Learning Objectives | Editorial Information

Deprescribing refers to lowering or stopping medications that might be causing harm or no longer providing benefit. It’s done in a planned, collaborative, and supervised way rather than simply the patient stopping the medications independently.

In This Issue

Article

Prescription CBD Is Available, But Are We Ready to Use It?

Topics: Anxiety | Cannabidiol | Psychopharmacology

Your patient comes in with a new medication on his list: CBD oil. He started taking it for anxiety and wants to know if it’s safe. You hedge, explaining that there is limited information available on unregulated products, but the patient is persistent. He says CBD oil is available as a prescription, and wonders if you could write one for it.

Read More
Expert Q&A

Deprescribing Medication

Topics: Deprescribing | Psychopharmacology

Deprescribing refers to lowering or stopping medications that might be causing harm or no longer providing benefit. It’s done in a planned, collaborative, and supervised way rather than simply the patient stopping the medications independently.

Read More
Ask The Editor

Wellbutrin Augmentation: When Does It Work?

Topics: Depression | Treatment-Resistant Depression | Wellbutrin

Dear Dr. Aiken: In the July/August 2018 issue, you wrote that ­bupropion (Wellbutrin) augmentation does not work in ­treatment-resistant depression (TRD). So why do we see it work so often in practice?

Read More
Research Update

Cannabidiol for Schizophrenia

Topics: Cannabidiol | Research Update | Schizophrenia

In this pilot study, investigators evaluated the benefits of cannabidiol (CBD), which is one of the two main active components of marijuana (the other being THC), for the treatment of ­schizophrenia.

Read More
Research Update

Is Ketamine Just Another Opiate?

Topics: Antidepressants | Depression | Ketamine | Opioids | Research Update

Ketamine’s rapid antidepressant effects have now been demonstrated in over two dozen double-blind, placebo-controlled trials, but how it works is less clear. For many years, NMDA receptor antagonism was thought responsible, but other NMDA antagonists have not worked well in depression.

Read More
News of Note

Brexanolone: A New Treatment for Postpartum Depression

Topics: News of Note

There is a need for rapid treatment in postpartum depression, as each month of this potentially severe condition can take a toll on infant development. That is why brexanolone (Zulresso), which was recently fast-tracked for approval by the FDA, is causing such a splash.

Read More
CME Post-Test

CME Post-Test - Deprescribing, TCPR, January 2019

Topics: CME Post-Test

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 1 CME credit.

Read More